Burns & Levinson announced that it represented privately-held Lowell Therapeutics, Inc. in the company’s $32.5 million sale to AcelRx Pharmaceuticals (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The deal, which was announced on November 15, 2021, closed on January 10, 2022.
Please fill out your information to be added to our mailing list, then select your publications of interest.* denotes required field
Welcome to the eBriefcase Management Center. As you assemble your personalized eBriefcase, you may drag to reorder or delete items. Once assembled, you can create a PDF of your eBriefcase.